Comments 1 - 6 of 6 Search these comments
It's hard to figure out how so many in the institutions throughout our society could abandon their oaths and their conscience so quickly and universally.

Anti-Masker
Well you gotta hand it to him, he says the thing all the doomers want to just come out and say. Great Britain also said "screw your freedom" a couple centuries ago, and we went to war over it. The authoritarians are back and the tree of liberty needs watering.
Journal of Vascular Surgery: Venous and Lymphatic Disorders
Available online 2 August 2021
Journal of Vascular Surgery: Venous and Lymphatic Disorders
Three cases of acute venous thromboembolism in females following vaccination for COVID-19
E.A.AndraskaR.KulkarniM.ChaudharyU.Sachdev ...
Here, we are the first to report venous thrombotic complications within days of administration of the mRNA-1273 (Moderna) vaccine. We present a series of three women who developed venous thromboembolism (VTE) following mRNA-1273 vaccination at a single healthcare system.
Keywords
Venous thromboembolism pulmonary embolism deep venous thrombosis COVID-19
Introduction
In response to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19 pandemic), four vaccinations have been rapidly developed worldwide. Two of these vaccines utilize mRNA coded to the spike protein antigen of SARS-CoV-2, and two use a viral vector for vaccination1. Three of these vaccines have been approved in the United States and since December 2020, the United States has vaccinated over 60 million people.
...there has been growing documentation of serious thrombotic complications after administration of COVID-19 vaccines2,3. Further, there have been recent reports of cerebral venous sinus thrombosis in women after receiving the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine4; which has caused the US Food and Drug Association (FDA) to recommend a pause in its use in the United States.
The recent reports of cerebral venous sinus thrombosis (CVST) following administration of CoViD-19 viral vector vaccines (AZ/Oxford and J&J/Janssen) have a peculiar clinical presentation exhibiting haemorrhage, blood clots and thrombocytopenia.
The vaccine may therefore spur the brain cells to produce CoViD spike proteins that may lead to an immune response against brain cells, or it may spark a spike protein-induced thrombosis. This may explain the peculiar incidences of the fatal CVST observed with viral vector-based CoViD-19 vaccines. There is very little information in the public domain to assess the biodistribution of all genetic vaccines, however, it is anticipated that if it is characteristic to the viral vector employed in the vaccine, then the other vaccines using similar technology may also lead to the same safety concerns. Some examples of these vaccines include AstraZeneca/Oxford (Chimp adenoviral vector), J&J/Janssen (Human adenoviral vector 26), CanSinoBio (Human adenoviral vector 5), and Sputnik V (Human adenoviral vectors 26 and 5)
The detailed biodistribution data including pharmacokinetics of various CoViD vaccines were not conducted by the vaccine manufacturers because the studies demonstrating biodistribution of antigens were considered ‘not required' by the regulatory authorities...
https://www.bmj.com/content/373/bmj.n958/rr-1